Literature DB >> 24328833

Atypical multifocal Dravet syndrome lacks generalized seizures and may show later cognitive decline.

Young Ok Kim1, Susannah Bellows, Jacinta M McMahon, Xenia Iona, John Damiano, Leanne Dibbens, Kent Kelley, Deepak Gill, J Helen Cross, Samuel F Berkovic, Ingrid E Scheffer.   

Abstract

AIM: To show that atypical multifocal Dravet syndrome is a recognizable, electroclinical syndrome associated with sodium channel gene (SCN1A) mutations that readily escapes diagnosis owing to later cognitive decline and tonic seizures.
METHOD: Eight patients underwent electroclinical characterization. SCN1A was sequenced and copy number variations sought by multiplex ligation-dependent probe amplification.
RESULTS: All patients were female (age range at assessment 5-26y) with median seizure onset at 6.5 months (range 4-19mo). The initial seizure was brief in seven and status epilepticus only occurred in one; three were febrile. Focal seizures occurred in four patients and bilateral convulsion in the other four. All patients developed multiple focal seizure types and bilateral convulsions, with seizure clusters in six. The most common focal seizure semiology (six out of eight) comprised unilateral clonic activity. Five also had focal or asymmetric tonic seizures. Rare or transient myoclonic seizures occurred in six individuals, often triggered by specific antiepileptic drugs. Developmental slowing occurred in all: six between 3 years and 8 years, and two around 1 year 6 months. Cognitive outcome varied from severe to mild intellectual disability. Multifocal epileptiform discharges were seen on electroencephalography. Seven out of eight patients had SCN1A mutations.
INTERPRETATION: Atypical, multifocal Dravet syndrome with SCN1A mutations may not be recognized because of later cognitive decline and frequent tonic seizures.
© 2013 Mac Keith Press.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24328833     DOI: 10.1111/dmcn.12322

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  4 in total

1.  Gene Panel Testing in Epileptic Encephalopathies and Familial Epilepsies.

Authors:  Rikke S Møller; Line H G Larsen; Katrine M Johannesen; Inga Talvik; Tiina Talvik; Ulvi Vaher; Maria J Miranda; Muhammad Farooq; Jens E K Nielsen; Lene Lavard Svendsen; Ditte B Kjelgaard; Karen M Linnet; Qin Hao; Peter Uldall; Mimoza Frangu; Niels Tommerup; Shahid M Baig; Uzma Abdullah; Alfred P Born; Pia Gellert; Marina Nikanorova; Kern Olofsson; Birgit Jepsen; Dragan Marjanovic; Lana I K Al-Zehhawi; Sofia J Peñalva; Bente Krag-Olsen; Klaus Brusgaard; Helle Hjalgrim; Guido Rubboli; Deb K Pal; Hans A Dahl
Journal:  Mol Syndromol       Date:  2016-08-20

2.  Pharmacological characterization of an antisense knockdown zebrafish model of Dravet syndrome: inhibition of epileptic seizures by the serotonin agonist fenfluramine.

Authors:  Yifan Zhang; Angéla Kecskés; Daniëlle Copmans; Mélanie Langlois; Alexander D Crawford; Berten Ceulemans; Lieven Lagae; Peter A M de Witte; Camila V Esguerra
Journal:  PLoS One       Date:  2015-05-12       Impact factor: 3.240

3.  A Study among the Genotype, Functional Alternations, and Phenotype of 9 SCN1A Mutations in Epilepsy Patients.

Authors:  Daniela Kluckova; Miriam Kolnikova; Lubica Lacinova; Bohumila Jurkovicova-Tarabova; Tomas Foltan; Viktor Demko; Ludevit Kadasi; Andrej Ficek; Andrea Soltysova
Journal:  Sci Rep       Date:  2020-06-24       Impact factor: 4.379

Review 4.  Benign and severe early-life seizures: a round in the first year of life.

Authors:  Piero Pavone; Giovanni Corsello; Martino Ruggieri; Silvia Marino; Simona Marino; Raffaele Falsaperla
Journal:  Ital J Pediatr       Date:  2018-05-15       Impact factor: 2.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.